Report of Foreign Issuer (6-k)
February 07 2019 - 2:53PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE
13a-16
OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2019
Commission File Number:
001-31368
SANOFI
(Translation of
registrants name into English)
54, rue La
Boétie, 75008 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form
20-F
or Form
40-F.
Form
20-F ☒
Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by
Regulation
S-T
Rule 101(b)(1): ☐
Indicate by check mark if the registrant is
submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7): ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule
12g3-2(b)
under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If Yes marked, indicate below the file number assigned to the registrant in connection with Rule
12g3-2(b):
82-
In February 2019, Sanofi issued the press releases and the statement attached hereto as Exhibit 99.1, 99.2, 99.3,
99.4 and 99.5 which are incorporated herein by reference.
Exhibit List
|
|
|
Exhibit No.
|
|
Description
|
|
|
Exhibit 99.1
|
|
Press release dated February 7, 2019: Sanofi delivers 2018 business EPS growth of 5.1% at CER
|
|
|
Exhibit 99.2
|
|
Press release dated February 6, 2019: Sanofis Board of Directors notes the resignation of Christian Mulliez and
co-opts
Christophe Babule as Director
|
|
|
Exhibit 99.3
|
|
Press release dated February 6, 2019: FDA approves Cablivi
®
(caplacizumab-yhdp), the first Nanobody
®
-based
medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
|
|
|
Exhibit 99.4
|
|
Press release dated February 5, 2019: Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
|
|
|
Exhibit 99.5
|
|
Sanofis Product Sales Statement, for the Product Sales Measuring Period Ended December 31, 2018
|
2
Exhibit Index
|
|
|
Exhibit No.
|
|
Description
|
|
|
Exhibit 99.1
|
|
Press release dated February 7, 2019: Sanofi delivers 2018 business EPS growth of 5.1% at CER
|
|
|
Exhibit 99.2
|
|
Press release dated February 6, 2019: Sanofis Board of Directors notes the resignation of Christian Mulliez and
co-opts
Christophe Babule as Director
|
|
|
Exhibit 99.3
|
|
Press release dated February 6, 2019: FDA approves Cablivi
®
(caplacizumab-yhdp), the first Nanobody
®
-based
medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
|
|
|
Exhibit 99.4
|
|
Press release dated February 5, 2019: Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
|
|
|
Exhibit 99.5
|
|
Sanofis Product Sales Statement, for the Product Sales Measuring Period Ended December 31, 2018
|
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
Dated: February 7, 2019
|
|
|
|
|
|
SANOFI
|
|
|
|
|
|
|
|
|
By
|
|
/s/ Alexandra Roger
|
|
|
|
|
|
|
Name:
|
|
Alexandra Roger
|
|
|
|
|
|
|
Title:
|
|
Head of Securities Law and Capital Markets
|
4
Sanofi (PK) (USOTC:SNYNF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (PK) (USOTC:SNYNF)
Historical Stock Chart
From Apr 2023 to Apr 2024